Joinn Laboratories (China) Co (SHSE:603127) Total Liabilities : ¥1,740 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Total Liabilities?

Joinn Laboratories (China) Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥1,740 Mil.

Joinn Laboratories (China) Co's quarterly Total Liabilities declined from Sep. 2023 (¥1,992.52 Mil) to Dec. 2023 (¥1,746.12 Mil) and declined from Dec. 2023 (¥1,746.12 Mil) to Mar. 2024 (¥1,739.53 Mil).

Joinn Laboratories (China) Co's annual Total Liabilities increased from Dec. 2021 (¥1,392.64 Mil) to Dec. 2022 (¥2,173.35 Mil) but then declined from Dec. 2022 (¥2,173.35 Mil) to Dec. 2023 (¥1,746.12 Mil).

Joinn Laboratories (China) Co Total Liabilities Historical Data

The historical data trend for Joinn Laboratories (China) Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Total Liabilities Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

652.34

951.09

1,392.64

2,173.35

1,746.12

Joinn Laboratories (China) Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,185.94	2,195.25	1,992.52	1,746.12	1,739.53

Joinn Laboratories (China) Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Joinn Laboratories (China) Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1467.365	+	(41.925	+	236.829
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,746

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	10027.16	-	8281.04
	=	1,746

Joinn Laboratories (China) Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1502.564	+	(35.532	+	201.43
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,740

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	9733.254	-	7993.728
	=	1,740

Joinn Laboratories (China) Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (SHSE:603127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

06127:Hong Kong

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yao Da Lin	Director
Sun Yun Xia	Director
Zuo Cong Lin	Director
Gao Da Peng	Director
Li Ye	Supervisors
Gu Xiao Lei	Director
Feng Yu Xia	Director
Gu Jing Liang	senior management
Yu Ai Shui	senior management
Yin Li Li	Supervisors
Sun Hui Ye	Supervisors
Gu Mei Fang	Director

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines